Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have been assigned a consensus recommendation of “Moderate Buy” from the four research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $37.50.

Several brokerages have commented on INTS. Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Finally, Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th.

Intensity Therapeutics Trading Down 2.1%

NASDAQ INTS traded down $0.09 during trading on Tuesday, hitting $4.20. The company had a trading volume of 26,259 shares, compared to its average volume of 43,618. The company’s fifty day moving average is $4.24 and its 200-day moving average is $5.68. Intensity Therapeutics has a one year low of $3.51 and a one year high of $43.50. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. The company has a market cap of $11.34 million, a price-to-earnings ratio of -0.74 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). On average, sell-side analysts predict that Intensity Therapeutics will post -2.7 earnings per share for the current year.

Hedge Funds Weigh In On Intensity Therapeutics

A number of institutional investors have recently added to or reduced their stakes in INTS. Corient Private Wealth LLC purchased a new stake in shares of Intensity Therapeutics in the 4th quarter worth about $41,000. State Street Corp increased its stake in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares in the last quarter. Jane Street Group LLC purchased a new position in Intensity Therapeutics during the 4th quarter valued at about $26,000. Geode Capital Management LLC lifted its position in Intensity Therapeutics by 77.8% during the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after acquiring an additional 201,357 shares during the period. Finally, Mesirow Financial Investment Management Inc. boosted its stake in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after acquiring an additional 51,000 shares in the last quarter. Institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.